` EW (Edwards Lifesciences Corp) vs S&P 500 Comparison - Alpha Spread

EW
vs
S&P 500

Over the past 12 months, EW has underperformed S&P 500, delivering a return of -13% compared to the S&P 500's 12% growth.

Stocks Performance
EW vs S&P 500

Loading

Performance Gap
EW vs S&P 500

Loading

Performance By Year
EW vs S&P 500

Loading
EW
S&P 500
Add Stock

Competitors Performance
Edwards Lifesciences Corp vs Peers

Edwards Lifesciences Corp
Glance View

Economic Moat
None
Market Cap
45.8B USD
Industry
Health Care

Nestled at the intersection of medical innovation and patient care, Edwards Lifesciences Corp. has long been a pioneer in the field of heart disease solutions. Emerging from its origins in the 1950s, the company has consistently focused on advancing heart valve technology, a critical area given the prevalence and severity of cardiovascular diseases. Their journey began with the development of the first artificial heart valve, setting a foundation of innovation that continues to propel the company forward. Today, Edwards is renowned for its leadership in transcatheter aortic valve replacement (TAVR) technology, an area that revolutionizes the treatment of aortic stenosis, a condition that narrows heart valves and impedes blood flow. This shift from open-heart surgeries to less invasive procedures, facilitated by Edwards' products, has marked a significant turning point in patient care, minimizing recovery times and enhancing patient outcomes. Financially, Edwards Lifesciences thrives on a robust business model centered around its technologically advanced heart valve systems and critical care technologies. The company operates through a direct sales force as well as strategic partnerships, ensuring their devices reach hospitals and healthcare providers globally. Their commitment to research and development ensures a steady pipeline of innovative products, which not only differentiates them in the market but also drives their profitability. Revenue streams are primarily fueled by the sales of their TAVR systems, surgical heart valves, and monitoring technologies—each designed to meet the complex and evolving needs of patients with structural heart diseases. By continually investing in cutting-edge technology and expanding their global reach, Edwards Lifesciences not only supports its bottom line but also positions itself as a leader in the transformative field of medical device innovation.

EW Intrinsic Value
55.491 USD
Overvaluation 29%
Intrinsic Value
Price
Back to Top